Biotech Drugmaker Pulls Plug on Ineffective Skin Drug

Zai Lab Ltd. has halted development of a key skin disease treatment after it failed in clinical trials, spotlighting the risks faced by a new generation of Chinese startups as they try to tap their nation’s growing drug market.
Zai made the move after the drug, ZL-3101 or Fugan, showed no difference in effectiveness compared with a placebo in a trial involving 295 Chinese patients with mild to moderate subacute eczema, the company said in a statement.
Zai had obtained worldwide rights to the drug from British giant GlaxoSmithKline PLC (GSK) in 2016. The company is one of a growing number of Chinese startups hoping to capitalize on an expected boom in demand for such treatments from an increasingly affluent local populace that can afford more-expensive medicines.
Zai CEO Samantha Du called the result “disappointing,” but added the company will redirect the resources to other “clinical-stage assets and opportunities.”
Founded in 2013, Zai Lab is a clinical-stage biopharmaceutical firm that focuses on cancer, infectious disease and auto-immune drug development. The discontinued skin disease drug trial was one of the three for which Zai held global rights in a broader pipeline with seven candidates.
In 2016, one of GSK’s China units sold Zai the right to develop and commercialize two products, including the skin disease treatment, for a nonrefundable upfront payment of 4.5 million yuan ($660,000) plus undisclosed milestone payments, according to the contract at that time.
The drug is a botanical formulation that was expected to work as an alternative to the steroids that are currently the main form of treatment and are known to have many side effects associated with long-term use.
The second-stage clinical trial had only involved patients in China and had started in the second quarter of 2017. The setback sent Zai’s New York-listed shares down 1.08% on Friday.
Contact reporter Coco Feng (renkefeng@caixin.com)

- 1Cover Story: China’s Factory Exodus Is Turning Vietnam Into the World’s Assembler
- 2Meituan Enters Open-Source AI Race With LongCat Model
- 3Ex-UBS Banker in Hong Kong Jailed 10 Years for Laundering $17.2 Million
- 4End of U.S. Tax Exemption Hits Chinese Air Cargo Carriers Differently
- 5Alipay Fined by Luxembourg Regulator for Anti-Money Laundering Breaches
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas